Show simple item record

dc.contributor.authorEvangelia, Sereti
dc.contributor.authorTheodosia, Karagianellou
dc.contributor.authorIoanna, Kotsoni
dc.contributor.authorDimitrios, Magouliotis
dc.contributor.authorKonstantinos, Kamposioras
dc.contributor.authorEngin, Ulukaya
dc.contributor.authorNikos, Sakellaridis
dc.contributor.authorDimitrios, Zacharoulis
dc.contributor.authorKonstantinos, Dimas
dc.date.accessioned2020-08-30T20:07:20Z
dc.date.available2020-08-30T20:07:20Z
dc.date.issued2018
dc.identifier.citationEvangelia, S., Theodosia, K., Ioanna, K., Dimitrios, M., Konstantinos, K., Engin, U., … Konstantinos, D. (2018). Patient Derived Xenografts (PDX) for personalized treatment of pancreatic cancer: emerging allies in the war on a devastating cancer? JOURNAL OF PROTEOMICS, 188, 107–118. https://doi.org/10.1016/j.jprot.2018.01.012en_US
dc.identifier.issn1874-3919
dc.identifier.issn1876-7737
dc.identifier.urihttps://doi.org/10.1016/j.jprot.2018.01.012
dc.identifier.urihttps://hdl.handle.net/20.500.12713/746
dc.descriptionSereti, Evangelia/0000-0002-5947-9971; Magouliotis, Dimitrios/0000-0001-5417-6392; Sakellaridis, Nikos/0000-0001-9193-7787en_US
dc.descriptionWOS: 000445719400011en_US
dc.descriptionPubMed: 29398619en_US
dc.descriptionEngin, Ulukaya (isu author)
dc.description.abstractThe prognosis of pancreatic ductal adenocarcinoma (PDAC), the eighth most lethal cancer for men and ninth for women worldwide, remains dismal. The increasing rates of deaths by PDAC indicate that the overall management of the disease in 21st century is still insufficient. Thus it is obvious that there is an unmet need to improve management of PDAC by finding new biomarkers to screen high risk patients, confirm diagnosis, and predict response to treatment as well more efficacious and safer treatments. Patient Derived Xenografts (PDX) have been developed as a new promising tool in an effort to mirror genetics, tumor heterogeneity and cancer micro environment of the primary tumor. Herein we aim to give an updated overview of the current status and the perspectives of PDX in the search for the identification of novel biomarkers and improved therapeutic outcomes for PDAC but also their use as a valuable tool towards individualized treatments to improve the outcome of the disease. Furthermore, we critically review the applications, advantages, limitations, and perspectives of PDX in the research towards an improved management of PDAC. Significance: This review provides a comprehensive overview of the current status and the potential role as well as the challenges of PDX in the road to fight one of the most lethal cancers in the developed countries, pancreatic ductal adenocarcinoma.en_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.relation.isversionof10.1016/j.jprot.2018.01.012en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPancreatic Ductal Adenocarcinomaen_US
dc.subjectPatient Derived Xenograftsen_US
dc.subjectBiomarkersen_US
dc.subjectDrug Discoveryen_US
dc.subjectPersonalized Medicineen_US
dc.titlePatient derived xenografts (PDX) for personalized treatment of pancreatic cancer: emerging allies in the war on a devastating cancer?en_US
dc.typearticleen_US
dc.contributor.departmentİstinye Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümüen_US
dc.contributor.authorID0000-0003-4875-5472en_US
dc.contributor.institutionauthorUlukaya, Enginen_US
dc.identifier.volume188en_US
dc.identifier.startpage107en_US
dc.identifier.endpage118en_US
dc.relation.journalJournal of Proteomicsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record